Recently, great progress has been achieved in this field with the approval of LUXTURNATM by FDA for the gene therapy of LCA, RPE65 mutation-associated retinal dystrophy (Darrow, 2019). This evidence concerns the gene RPE65 and Leber congenital amaurosis.